Google has suspended business activity involving the transfer of hardware, software and key technical services with Huawei. Analysts say that could be a big blow to the...Technologyread more
Global dividends reached a first-quarter record of $263.3 billion, rising 7.8% despite concerns about the world economy, according to new reach Monday.Marketsread more
Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
Huawei claims it has developed its own operating system for smartphones and laptops for "extenuating circumstances."Technologyread more
Current geopolitical tensions are making it harder and harder for oil-producing nations to make decisions that will help stabilize crude prices, Russian Energy Minister...Oilread more
Oil prices jumped on Monday after Saudi Energy Minister Khalid al-Falih indicated there was a consensus among OPEC and allied oil producers to continue limiting supply.Energyread more
Bank, property and healthcare stocks jumped, pushing Australian markets to a 11-year high, as Scott Morrison and the Liberal-led conservation government are poised for a...World Marketsread more
Trump's threat, posted on Twitter, comes amid rising international tensions in the Middle East as the U.S. has dispatched a carrier strike group and bomber task force to the...Politicsread more
Trade tensions between the U.S. and China stalled a global recovery and are continuing to endanger investment and growth, the secretary general of the OECD warned Monday.World Economyread more
Prime Minister Narendra Modi and his Bharatiya Janata Party are set to form the new government again, exit polls from India's month-long parliamentary elections show. But past...Electionsread more
The latest crisis in the uneasy French-German relationship was accelerated by Trump's decision to stop Germany's comfortable and decades-old free-riding on trade and security...Europe Politicsread more
HERSHEY, Pa. and ROCKVILLE, Md., April 2, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ( "ITI") a privately-held biotechnology company pioneering next-generation vaccines based on its proprietary LAMP technology, today announces it will be presenting at the 15th Annual World Vaccine Congress, which will be held at the Walter E. Washington Convention Center in Washington, D.C. on April 7-9, 2015. The company will be presenting on April 8th, and will be exhibiting at booth #16.
ITI's presentations will be at the following times:
Title: Nucleic Acid Vaccines for Oncology incorporating LAMP-Vax Technology
Presenter: Dr. Duane Mitchell, University of Florida
Time: 3:40 pm (EDT)
Title: DNA Vaccines for animal health utilizing LAMP-Vax Technology
Presenter: Dr. Teri J. Heiland, VP, R&D
Time: 5:10 pm (EDT)
"This is an important conference for ITI as it gathers the top thinkers from the world of vaccines together to discuss new strategies and approaches to vaccination, as well as new areas where vaccines are beginning to be explored," said William Hearl, Ph.D., CEO of Immunomic Therapeutics, Inc. "Our LAMP-vax technology has numerous applications and we are looking forward to sharing our progress with our colleagues while expanding our relationships with potential partners and collaborators."
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies Currently, the company is pursuing three main allergy programs:
For more information about ITI and LAMP Technology, please visit www.immunomix.com.
CONTACT: Jules Abraham JQA Partners, Inc. email@example.com (917) 885-7378 Sia Anagnostou Immunomic Therapeutics, Inc firstname.lastname@example.org http://www.immunomix.com (717) 327-1822Source:Immunomic Therapeutics, Inc.